CY1116296T1 - Χρηση vegf και ομολογων στη θεραπευτικη αγωγη νευρωνικων διαταραχων - Google Patents

Χρηση vegf και ομολογων στη θεραπευτικη αγωγη νευρωνικων διαταραχων

Info

Publication number
CY1116296T1
CY1116296T1 CY20151100131T CY151100131T CY1116296T1 CY 1116296 T1 CY1116296 T1 CY 1116296T1 CY 20151100131 T CY20151100131 T CY 20151100131T CY 151100131 T CY151100131 T CY 151100131T CY 1116296 T1 CY1116296 T1 CY 1116296T1
Authority
CY
Cyprus
Prior art keywords
vegf
bonds
treatment
neural disorders
disease
Prior art date
Application number
CY20151100131T
Other languages
English (en)
Inventor
Peter Carmeliet
Désiré Collen
Bert Oosthuyse
Original Assignee
Vib Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vib Vzw filed Critical Vib Vzw
Publication of CY1116296T1 publication Critical patent/CY1116296T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knockout animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Abstract

Η παρούσα εφεύρεση αφορά τη χρήση VEGF-B για την κατασκευή ενός φαρμάκου για τη θεραπευτική αγωγή οποιουδήποτε από μετωποκροταφική άνοια λοβού, νόσο Alzheimer, νόσο Parkinson, νόσο Huntington, και διαταραχές κινητήριων νευρώνων.
CY20151100131T 2000-04-12 2015-02-10 Χρηση vegf και ομολογων στη θεραπευτικη αγωγη νευρωνικων διαταραχων CY1116296T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00201325 2000-04-12
EP00203382 2000-09-29
EP10178853.7A EP2277528B1 (en) 2000-04-12 2001-04-12 Use of VEGF and homologues to treat neuron disorders

Publications (1)

Publication Number Publication Date
CY1116296T1 true CY1116296T1 (el) 2017-02-08

Family

ID=26072122

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20111101176T CY1112126T1 (el) 2000-04-12 2011-11-30 Χρηση toy vegf 165 και των ομολογων για την αγωγη διαταραχων των νευρωνων
CY20151100131T CY1116296T1 (el) 2000-04-12 2015-02-10 Χρηση vegf και ομολογων στη θεραπευτικη αγωγη νευρωνικων διαταραχων
CY20151101015T CY1116933T1 (el) 2000-04-12 2015-11-11 Χρηση vegf και ομολογων στη θεραπευτικη αγωγη νευρωνικων διαταραχων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20111101176T CY1112126T1 (el) 2000-04-12 2011-11-30 Χρηση toy vegf 165 και των ομολογων για την αγωγη διαταραχων των νευρωνων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20151101015T CY1116933T1 (el) 2000-04-12 2015-11-11 Χρηση vegf και ομολογων στη θεραπευτικη αγωγη νευρωνικων διαταραχων

Country Status (10)

Country Link
US (5) US7226908B2 (el)
EP (3) EP2295070B1 (el)
AT (1) ATE526981T1 (el)
AU (2) AU6896801A (el)
CA (3) CA2404616C (el)
CY (3) CY1112126T1 (el)
DK (3) DK2277528T3 (el)
ES (3) ES2372809T3 (el)
PT (3) PT2277528E (el)
WO (1) WO2001076620A2 (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2404616C (en) * 2000-04-12 2009-08-18 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of vegf and homologues to treat neuron disorders
DE60223556T2 (de) * 2001-08-10 2008-09-18 Imclone Systems, Inc. Medizinische verwendung von stammzellen, die vegfr-1 exprimieren
US7981863B2 (en) 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
EP1663293A2 (en) * 2003-09-23 2006-06-07 Ludwig Institute For Cancer Research Vege-cor vege-d materials and methods for stimulation of neural stem cells
ATE478678T1 (de) * 2004-05-27 2010-09-15 Vib Vzw Behandlung von amyotrohper lateralsklerose
US20070021421A1 (en) * 2005-07-25 2007-01-25 Hampton Thomas G Measurement of gait dynamics and use of beta-blockers to detect, prognose, prevent and treat amyotrophic lateral sclerosis
WO2007023479A2 (en) * 2005-08-23 2007-03-01 Royal College Of Surgeons In Ireland Treatment of central nervous system injury
CN101534865A (zh) * 2005-10-19 2009-09-16 Ibc药品公司 生物活性装配体的制备方法及其用途
GB0803912D0 (en) * 2008-02-29 2008-05-07 Univ Bristol Novel Uses of VEGFxxxb
ES2376930B1 (es) * 2009-02-05 2013-01-24 Universidad Del Pais Vasco Método para el tratamiento de enfermedades neurodegenerativas.
US8741850B2 (en) 2009-07-24 2014-06-03 Advanced Accelerator Applications S.A. Compounds modulators of VEGF activity and uses thereof
US9663564B2 (en) 2013-03-15 2017-05-30 The Regents Of The University Of California Vectors and methods to treat ischemia
WO2014035433A1 (en) * 2012-08-31 2014-03-06 Jan Nolta Genetically modified msc and therapeutic methods
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
RU2639175C1 (ru) * 2016-11-14 2017-12-20 Общество с ограниченной ответственностью "НекстГен" Способ индукции регенерации периферического нерва
US20210154270A1 (en) * 2018-04-12 2021-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anti-aging compositions and methods of use
CN113057142B (zh) * 2021-03-30 2022-12-09 四川大学华西医院 一种视网膜内和/或视网膜下纤维化动物模型的构建方法
WO2023214189A1 (en) * 2022-05-05 2023-11-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and composition for treating neurodegenerative disorder

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3013780A (en) 1957-12-09 1961-12-19 Shell Oil Co Gas-liquid contacting apparatus with shutter trays
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
DE69434538T2 (de) 1994-03-08 2006-08-10 Human Genome Sciences, Inc. Vaskulärer endothelialer Wachstumsfaktor 2
CN1229498C (zh) 1996-02-21 2005-11-30 美国国有卫生与人类服务部 重组的核糖核酸酶蛋白质
US6013780A (en) 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
US5965363A (en) 1996-09-19 1999-10-12 Genetrace Systems Inc. Methods of preparing nucleic acids for mass spectrometric analysis
AU6614398A (en) * 1997-01-17 1998-08-07 Institut National De La Sante Et De La Recherche Medicale Adenoviral-vector-mediated gene transfer into medullary motor neurons
NZ314594A (en) 1997-04-14 1998-06-26 Patchett Ag Air Ltd A spray boom including outlet nozzle clearing means and actuators therefor
JP2002505873A (ja) * 1998-03-13 2002-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 血管内皮増殖因子２
ES2389387T3 (es) * 1998-03-17 2012-10-25 Genentech, Inc. Polipéptidos homólogos de VEGF y de BMP1
GB2358020A (en) 1998-09-23 2001-07-11 Oxford Biomedica Ltd Polynucleotide constructs and uses thereof
WO2000062798A2 (en) * 1999-04-15 2000-10-26 St. Elizabeth's Medical Center, Inc. Angiogenic growth factors for treatment of peripheral neuropathy
US7125856B1 (en) * 1999-04-15 2006-10-24 St. Elizabeth's Medical Center Of Boston, Inc. Angiogenic growth factors for treatment of peripheral neuropathy
AU6733400A (en) * 1999-08-30 2001-03-26 Sumitomo Pharmaceuticals Company, Limited Novel uses of semaphorin and vegf
US6930089B2 (en) * 2000-02-04 2005-08-16 D. Collen Research Foundation Vzw Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic disease or stroke
CA2404616C (en) 2000-04-12 2009-08-18 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of vegf and homologues to treat neuron disorders
CA2451311A1 (en) * 2001-06-20 2003-01-03 Ludwig Institute For Cancer Research Stimulation of vascularization with vegf-b
US20040248796A1 (en) * 2003-02-04 2004-12-09 Kari Alitalo VEGF-B and PDGF modulation of stem cells
ATE478678T1 (de) * 2004-05-27 2010-09-15 Vib Vzw Behandlung von amyotrohper lateralsklerose

Also Published As

Publication number Publication date
ES2551160T3 (es) 2015-11-16
CY1116933T1 (el) 2017-04-05
EP2277528B1 (en) 2014-11-12
DK2295070T3 (en) 2015-11-16
CA2404616A1 (en) 2001-10-18
CA2659656A1 (en) 2001-10-18
CA2404616C (en) 2009-08-18
US20110288020A1 (en) 2011-11-24
EP2295070B1 (en) 2015-08-12
DK2277528T3 (en) 2015-01-26
ES2528217T3 (es) 2015-02-05
PT1272208E (pt) 2012-01-03
EP2277528A2 (en) 2011-01-26
AU2001268968B2 (en) 2006-10-19
US7888322B2 (en) 2011-02-15
PT2277528E (pt) 2015-02-05
CA2654413C (en) 2016-10-18
DK1272208T3 (da) 2011-10-31
EP1272208A2 (en) 2003-01-08
US7592314B2 (en) 2009-09-22
US7226908B2 (en) 2007-06-05
US20030105018A1 (en) 2003-06-05
US20070249539A1 (en) 2007-10-25
US20080032314A1 (en) 2008-02-07
WO2001076620A2 (en) 2001-10-18
EP1272208B1 (en) 2011-10-05
CY1112126T1 (el) 2015-11-04
ES2372809T3 (es) 2012-01-26
AU6896801A (en) 2001-10-23
EP2277528A3 (en) 2011-03-02
CA2654413A1 (en) 2001-10-18
US20100041601A1 (en) 2010-02-18
EP2295070A1 (en) 2011-03-16
ATE526981T1 (de) 2011-10-15
WO2001076620A3 (en) 2001-12-20
PT2295070E (pt) 2015-12-07

Similar Documents

Publication Publication Date Title
CY1116933T1 (el) Χρηση vegf και ομολογων στη θεραπευτικη αγωγη νευρωνικων διαταραχων
CY1121408T1 (el) Προληψη και θεραπεια συνουκλεϊνοπαθειας και αμυλοειδοπαθειας
DE602004021797D1 (de) Behandlung von alzheimer-krankheit und amyloider gehirnangiopathie
ATE427114T1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomíostase stírungen
WO2004041067A3 (en) Prevention and treatment of synucleinopathic disease
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
WO2004071431A3 (en) Method and composition for treating neurodegenerative disorders
BRPI0407662A (pt) derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas
ATE444077T1 (de) Präventiva und therapeutika für mit demyelinisierung-assozierten erkrankungen
DE60144366D1 (de) Neuroprotektive, antithrombotische und anti-entzündliche anwendungen von aktiviertem protein c
IL167848A (en) Use of brimonidine in the manufacture of a medicament for treating neurodegenerative conditions
WO2005046605A3 (en) Compositions and methods of treating neurological diseases
AU2002229928A1 (en) Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases
EP1297849A4 (en) CURATIVE AGENT FOR OPTICAL AND SIMILAR NERVE DISEASES
PT1235573E (pt) Associacao de riluzole e de gabapentina e sua utilizacao como medicamento no tratamento das doencas motoneuronais
WO2002076437A3 (en) Methods for treating neurodegenerative diseases including alzheimer's
WO2005025590A3 (en) Use of a dg280 protein product for preventing and treating metabolic disorders
WO2005067957A3 (en) Use of a dg147 protein product for preventing and treating metabolic disorders
RU2002103977A (ru) Способ лечения острого гнойного пиелонефрита